Surmodics (SRDX) Competitors

Surmodics (NASDAQ:SRDX) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Does the media prefer SRDX or SIBN?

In the previous week, SI-BONE had 9 more articles in the media than Surmodics. MarketBeat recorded 15 mentions for SI-BONE and 6 mentions for Surmodics. Surmodics' average media sentiment score of 1.07 beat SI-BONE's score of 0.73 indicating that Surmodics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surmodics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SI-BONE	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer SRDX or SIBN?

Surmodics presently has a consensus target price of $50.00, suggesting a potential upside of 29.13%. SI-BONE has a consensus target price of $23.00, suggesting a potential upside of 78.02%. Given SI-BONE's stronger consensus rating and higher probable upside, analysts plainly believe SI-BONE is more favorable than Surmodics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surmodics	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of SRDX or SIBN?

96.6% of Surmodics shares are held by institutional investors. Comparatively, 98.1% of SI-BONE shares are held by institutional investors. 8.9% of Surmodics shares are held by insiders. Comparatively, 3.9% of SI-BONE shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, SRDX or SIBN?

Surmodics has higher earnings, but lower revenue than SI-BONE. Surmodics is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surmodics	$126.08M	4.38	-$11.54M	-$0.81	-47.80
SI-BONE	$138.89M	3.90	-$43.34M	-$0.92	-14.04

Does the MarketBeat Community believe in SRDX or SIBN?

Surmodics received 170 more outperform votes than SI-BONE when rated by MarketBeat users. However, 68.16% of users gave SI-BONE an outperform vote while only 63.58% of users gave Surmodics an outperform vote.

Company	Underperform	Outperform
Surmodics	Outperform Votes 337 63.58%	Underperform Votes 193 36.42%
SI-BONE	Outperform Votes 167 68.16%	Underperform Votes 78 31.84%

Is SRDX or SIBN more profitable?

Surmodics has a net margin of -9.15% compared to SI-BONE's net margin of -23.82%. Surmodics' return on equity of -3.77% beat SI-BONE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surmodics	-9.15%	-3.77%	-2.54%
SI-BONE	-23.82%	-22.51%	-16.53%

Which has more risk & volatility, SRDX or SIBN?

Surmodics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Summary

Surmodics and SI-BONE tied by winning 9 of the 18 factors compared between the two stocks.